{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:56:03Z","timestamp":1783792563545,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Qatar National Research Fund and Weill Cornell Medical College"},{"name":"The International League of Association for Rheumatology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s10067-018-4245-5","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T04:26:04Z","timestamp":1533875164000},"page":"2947-2959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adolopment of the 2015 American College of Rheumatology guidelines"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-0272","authenticated-orcid":false,"given":"Thurayya","family":"Arayssi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manale","family":"Harfouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Darzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Al Emadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"A. Alnaqbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humeira","family":"Badsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida","family":"Al Balushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Elzorkany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Hammoudeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"Hazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Merashli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Omair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Salloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Uthman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeja","family":"Zahirovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Ziade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveendhara R.","family":"Bannuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"McAlindon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Nomier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Sch\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie A.","family":"Akl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,10]]},"reference":[{"issue":"3","key":"4245_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324","journal-title":"Arthritis Rheum"},{"key":"4245_CR2","doi-asserted-by":"crossref","unstructured":"Chatzidionysiou K, Emamikia S, Nam JL, Ramiro S, Smolen J, Van Der Heijde D, Dougados M, Bijlsma JWJ, Burmester G, Scholte-Voshaar M, Van Vollenhoven R, Landewe R (2016) Efficacy and safety of conventional and targeted synthetic disease-modifying antirheumatic drugs as well as glucocorticoids: a systematic literature review informing the 2016 update of the eular recommendations for the management of rheumatoid arthritis. In: Arthritis and rheumatology. Wiley, Hoboken","DOI":"10.1136\/annrheumdis-2016-210711"},{"issue":"6937","key":"4245_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature01661","volume":"423","author":"GS Firestein","year":"2003","unstructured":"Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423(6937):356\u2013361","journal-title":"Nature"},{"issue":"suppl 2","key":"4245_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.59","volume":"34","author":"T Pincus","year":"1995","unstructured":"Pincus T (1995) Long-term outcomes in rheumatoid arthritis. Rheumatology 34(suppl 2):59\u201373","journal-title":"Rheumatology"},{"issue":"7","key":"4245_CR5","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73(7):1316\u20131322","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4245_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/art.10897","volume":"48","author":"EK Rasch","year":"2003","unstructured":"Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC (2003) Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 48(4):917\u2013926","journal-title":"Arthritis Rheum"},{"issue":"9602","key":"4245_CR7","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370(9602):1861\u20131874","journal-title":"Lancet"},{"key":"4245_CR8","first-page":"204573","volume":"2013","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J (2013) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis: Annrheumdis 2013:204573","journal-title":"Ann Rheum Dis: Annrheumdis"},{"issue":"1","key":"4245_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landew\u00e9 R (2014) Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73(1):3\u20135","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4245_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12955-017-0754-1","volume":"15","author":"A Darzi","year":"2017","unstructured":"Darzi A, Harfouche M, Arayssi T, Alemadi S, Alnaqbi KA, Badsha H, Al Balushi F, Elzorkany B, Halabi H, Hamoudeh M, Hazer W, Masri B, Omair MA, Uthman I, Ziade N, Singh JA, Christiansen R, Tugwell P, Schunemann HJ, Akl EA (2017) Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment. Health Qual Life Outcomes 15(1):183. \n                    https:\/\/doi.org\/10.1186\/s12955-017-0754-1","journal-title":"Health Qual Life Outcomes"},{"key":"4245_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","volume":"81","author":"HJ Schunemann","year":"2017","unstructured":"Schunemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, Brignardello-Petersen R, Neumann I, Falavigna M, Alhazzani W, Santesso N, Zhang Y, Meerpohl JJ, Morgan RL, Rochwerg B, Darzi A, Rojas MX, Carrasco-Labra A, Adi Y, AlRayees Z, Riva J, Bollig C, Moore A, Yepes-Nunez JJ, Cuello C, Waziry R, Akl EA (2017) GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol 81:101\u2013110. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2016.09.009","journal-title":"J Clin Epidemiol"},{"key":"4245_CR12","doi-asserted-by":"publisher","first-page":"i2016","DOI":"10.1136\/bmj.i2016","volume":"353","author":"P Alonso-Coello","year":"2016","unstructured":"Alonso-Coello P, Schunemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Rada G, Rosenbaum S, Morelli A, Guyatt GH, Oxman AD (2016) GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction. BMJ (Clinical research ed) 353:i2016. \n                    https:\/\/doi.org\/10.1136\/bmj.i2016","journal-title":"BMJ (Clinical research ed)"},{"key":"4245_CR13","doi-asserted-by":"publisher","first-page":"i2089","DOI":"10.1136\/bmj.i2089","volume":"353","author":"P Alonso-Coello","year":"2016","unstructured":"Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Vandvik PO, Meerpohl J, Guyatt GH, Schunemann HJ (2016) GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines. BMJ (Clinical research ed) 353:i2089. \n                    https:\/\/doi.org\/10.1136\/bmj.i2089","journal-title":"BMJ (Clinical research ed)"},{"issue":"6","key":"4245_CR14","first-page":"249","volume":"106","author":"M Davoli","year":"2015","unstructured":"Davoli M, Moja L, Amato L, Ferroni E, Tirani M (2015) Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. Recenti Prog Med 106(6):249\u2013280","journal-title":"Recenti Prog Med"},{"issue":"1","key":"4245_CR15","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 68(1):1\u201326","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4245_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann HJ (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383\u2013394. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"4245_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, Johnston BC, Karanicolas P, Akl EA, Vist G, Kunz R, Brozek J, Kupper LL, Martin SL, Meerpohl JJ, Alonso-Coello P, Christensen R, Schunemann HJ (2013) GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol 66(2):173\u2013183. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2012.08.001","journal-title":"J Clin Epidemiol"},{"key":"4245_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","volume":"76","author":"HJ Sch\u00fcnemann","year":"2016","unstructured":"Sch\u00fcnemann HJ, Mustafa R, Brozek J, Santesso N, Alonso-Coello P, Guyatt G, Scholten R, Langendam M, Leeflang MM, Akl EA (2016) GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol 76:89\u201398","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"4245_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401\u2013406","journal-title":"J Clin Epidemiol"},{"key":"4245_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jclinepi.2016.07.006","volume":"80","author":"GH Guyatt","year":"2016","unstructured":"Guyatt GH, Alonso-Coello P, Schunemann HJ, Djulbegovic B, Nothacker M, Lange S, Murad MH, Akl EA (2016) Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol 80:3\u20137. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2016.07.006","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"4245_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, Meerpohl J, Post PN, Kunz R (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66(7):719\u2013725","journal-title":"J Clin Epidemiol"},{"key":"4245_CR22","first-page":"207526","volume":"2015","author":"MA Stoffer","year":"2015","unstructured":"Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B (2015) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis: Annrheumdis 2015:207526","journal-title":"Ann Rheum Dis: Annrheumdis"},{"key":"4245_CR23","first-page":"204588","volume":"2013","author":"C Gaujoux-Viala","year":"2014","unstructured":"Gaujoux-Viala C, Nam J, Ramiro S, Landew\u00e9 R, Buch MH, Smolen JS, Gossec L (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis: Annrheumdis 2013:204588","journal-title":"Ann Rheum Dis: Annrheumdis"},{"issue":"8","key":"4245_CR24","first-page":"673","volume":"62","author":"N Menon","year":"2014","unstructured":"Menon N, Kothari S, Gogna A, Sharma R (2014) Comparison of intra-articular glucocorticoid injections with DMARDs versus DMARDs alone in rheumatoid arthritis. J Assoc Physicians India 62(8):673\u2013676","journal-title":"J Assoc Physicians India"},{"issue":"1","key":"4245_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10067-013-2398-9","volume":"33","author":"D Cock De","year":"2014","unstructured":"De Cock D, Vanderschueren G, Meyfroidt S, Joly J, Westhovens R, Verschueren P (2014) Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice. Clin Rheumatol 33(1):125\u2013130","journal-title":"Clin Rheumatol"},{"issue":"1","key":"4245_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","volume":"74","author":"P Verschueren","year":"2015","unstructured":"Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J (2015) Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 74(1):27\u201334","journal-title":"Ann Rheum Dis"},{"key":"4245_CR27","first-page":"h1046","volume":"350","author":"DL Scott","year":"2015","unstructured":"Scott DL, Ibrahim F, Farewell V, O\u2019Keeffe AG, Walker D, Kelly C, Birrell F, Chakravarty K, Maddison P, Heslin M (2015) Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ (Clinical research ed) 350:h1046","journal-title":"BMJ (Clinical research ed)"},{"key":"4245_CR28","first-page":"203243","volume":"2013","author":"L Heimans","year":"2013","unstructured":"Heimans L, Wevers-de Boer K, Visser K, Goekoop R, van Oosterhout M, Harbers J, Bijkerk C, Speyer I, de Buck M, de Sonnaville P (2013) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis: Annrheumdis 2013:203243","journal-title":"Ann Rheum Dis: Annrheumdis"},{"key":"4245_CR29","first-page":"210713","volume":"2016","author":"JL Nam","year":"2017","unstructured":"Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, Bijlsma JW, Burmester GR, Dougados M, Scholte-Voshaar M (2017) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis: Annrheumdis 2016:210713","journal-title":"Ann Rheum Dis: Annrheumdis"},{"issue":"2","key":"4245_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4103\/injr.injr_37_17","volume":"12","author":"A Zanwar","year":"2017","unstructured":"Zanwar A, Ahmed S, Misra DP, Agarwal V, Sharma A, Wakhlu A, Negi VS (2017) Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Indian J Rheumatol 12(2):104","journal-title":"Indian J Rheumatol"},{"issue":"5","key":"4245_CR31","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O (2014) Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73(5):803\u2013809","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4245_CR32","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2016.13512","volume":"316","author":"J-E Gottenberg","year":"2016","unstructured":"Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot J-M, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B (2016) Non\u2013TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. Jama 316(11):1172\u20131180","journal-title":"Jama"},{"issue":"1","key":"4245_CR33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13075-015-0630-5","volume":"17","author":"SH Manders","year":"2015","unstructured":"Manders SH, Kievit W, Adang E, Brus HL, Moens HJB, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE (2015) Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther 17(1):134","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"4245_CR34","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/acr.22010","volume":"65","author":"JE Pope","year":"2013","unstructured":"Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS (2013) Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis Care Res 65(9):1401\u20131409","journal-title":"Arthritis Care Res"},{"issue":"1","key":"4245_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-015-0776-1","volume":"17","author":"LR Harrold","year":"2015","unstructured":"Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM (2015) Comparative effectiveness and safety of rituximab versus subsequent anti\u2013tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti\u2013tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther 17(1):256","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"4245_CR36","doi-asserted-by":"publisher","first-page":"A652","DOI":"10.1016\/j.jval.2015.09.2348","volume":"18","author":"T Dilla","year":"2015","unstructured":"Dilla T, Rentero M, Comellas M, Lizan L, Sacrist\u00e1n J (2015) Patients\u2019 preferences for rheumatoid arthritis treatments and their participation in the treatment decision-making process. A systematic review of the literature. Value Health 18(7):A652","journal-title":"Value Health"},{"key":"4245_CR37","first-page":"93","volume":"8","author":"TK Huynh","year":"2014","unstructured":"Huynh TK, \u00d8stergaard A, Egsmose C, Madsen OR (2014) Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence 8:93","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"4245_CR38","doi-asserted-by":"publisher","first-page":"e0149781","DOI":"10.1371\/journal.pone.0149781","volume":"11","author":"I Navarro-Mill\u00e1n","year":"2016","unstructured":"Navarro-Mill\u00e1n I, Herrinton LJ, Chen L, Harrold L, Liu L, Curtis JR (2016) Comparative effectiveness of etanercept and adalimumab in patient reported outcomes and injection-related tolerability. PLoS One 11(3):e0149781","journal-title":"PLoS One"},{"issue":"7","key":"4245_CR39","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/acr.22531","volume":"67","author":"I Nota","year":"2015","unstructured":"Nota I, Drossaert CH, Taal E, van de Laar MA (2015) Patients\u2019 considerations in the decision-making process of initiating disease-modifying antirheumatic drugs. Arthritis Care Res 67(7):956\u2013964","journal-title":"Arthritis Care Res"},{"issue":"7","key":"4245_CR40","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/acr.22265","volume":"66","author":"C Poulos","year":"2014","unstructured":"Poulos C, Hauber AB, Gonz\u00e1lez JM, Turpcu A (2014) Patients\u2019 willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res 66(7):1008\u20131015","journal-title":"Arthritis Care Res"},{"issue":"2","key":"4245_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3111\/13696998.2015.1099538","volume":"19","author":"J Harnett","year":"2016","unstructured":"Harnett J, Wiederkehr D, Gerber R, Gruben D, Koenig A, Bourret J (2016) Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis. J Med Econ 19(2):101\u2013112","journal-title":"J Med Econ"},{"issue":"4","key":"4245_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3111\/13696998.2014.893241","volume":"17","author":"B Meissner","year":"2014","unstructured":"Meissner B, Trivedi D, You M, Rosenblatt L (2014) Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ 17(4):259\u2013265","journal-title":"J Med Econ"},{"issue":"10","key":"4245_CR43","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/rheumatology\/keu039","volume":"53","author":"A Wailoo","year":"2014","unstructured":"Wailoo A, Hern\u00e1ndez Alava M, Scott IC, Ibrahim F, Scott DL (2014) Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. Rheumatology 53(10):1773\u20131777","journal-title":"Rheumatology"},{"issue":"5","key":"4245_CR44","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s12325-016-0318-5","volume":"33","author":"Z-Y Zhou","year":"2016","unstructured":"Zhou Z-Y, Griffith J, Du EX, Chin D, Betts KA, Ganguli A (2016) Economic burden of switching to a non-tumor necrosis factor inhibitor versus a tumor necrosis factor inhibitor biologic therapy among patients with rheumatoid arthritis. Adv Ther 33(5):807\u2013823","journal-title":"Adv Ther"},{"issue":"23","key":"4245_CR45","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1001\/jama.2013.281422","volume":"310","author":"VM Montori","year":"2013","unstructured":"Montori VM, Brito JP, Murad MH (2013) The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. Jama 310(23):2503\u20132504. \n                    https:\/\/doi.org\/10.1001\/jama.2013.281422","journal-title":"Jama"}],"updated-by":[{"DOI":"10.1007\/s10067-018-4282-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4245-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4245-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4245-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T19:15:11Z","timestamp":1565378111000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4245-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,10]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4245"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4245-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10067-018-4282-0","asserted-by":"object"}]},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,10]]},"assertion":[{"value":"16 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version of this article the first name of the co-author was incorrectly spelled as \u201cKhaled A. Alnaqbi\u201d. The correct spelling should have been \u201cKhalid A. Alnaqbi\u201d. This is now presented correctly in this article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}